A Retrospective Multicenter Italian Analysis of Epidemiological, Clinical and Histopathological Features in a Sample of Patients with Acinic Cell Carcinoma of the Parotid Gland.
acinic cell carcinoma
neck dissection
parotid
parotidectomy
salivary gland
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
02
10
2023
revised:
04
11
2023
accepted:
14
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
The acinic cell carcinoma (AciCC) of the parotid gland is a rare tumor with an indolent behavior; however, a subgroup of this tumor presents an aggressive behavior with a tendency to recur. The aim of this multicenter study was to identify and stratify those patients with AciCC at high risk of tumor recurrence. A retrospective study was carried out involving 77 patients treated with surgery between January 2000 and September 2022, in different Italian referral centers. Data about tumor characteristics and its recurrence were collected. The histological specimens and slides were independently reviewed by a senior pathologist coordinator (L.C.) and the institution's local head and neck pathologist. The patients' age average was 53.6 years, with a female prevalence in the group. The mean follow-up was 67.4 months (1-258, SD 59.39). The five-year overall survival (OS) was 83.2%. The 5-year disease-free survival (DFS) was 60% (95% CI 58.2-61.7). A high incidence of necrosis, extraglandular spread, lymphovascular invasion (LVI), atypical mitosis, and cellular pleomorphism was observed in the high-risk tumors compared to the low-risk ones. AciCC generally had an indolent behavior, optimal OS, DFS with few cervical node metastases, and rare distant relapses. This multicenter retrospective case series provides evidence of the need for clinical-epidemiological-histological stratification for patients at risk of poor outcomes. Our results suggest that the correct definition of high-risk AciCC should include tumor size, the presence of necrosis, extraglandular spread, LVI, atypical mitosis, and cellular pleomorphism.
Sections du résumé
BACKGROUND
BACKGROUND
The acinic cell carcinoma (AciCC) of the parotid gland is a rare tumor with an indolent behavior; however, a subgroup of this tumor presents an aggressive behavior with a tendency to recur. The aim of this multicenter study was to identify and stratify those patients with AciCC at high risk of tumor recurrence.
METHODS
METHODS
A retrospective study was carried out involving 77 patients treated with surgery between January 2000 and September 2022, in different Italian referral centers. Data about tumor characteristics and its recurrence were collected. The histological specimens and slides were independently reviewed by a senior pathologist coordinator (L.C.) and the institution's local head and neck pathologist.
RESULTS
RESULTS
The patients' age average was 53.6 years, with a female prevalence in the group. The mean follow-up was 67.4 months (1-258, SD 59.39). The five-year overall survival (OS) was 83.2%. The 5-year disease-free survival (DFS) was 60% (95% CI 58.2-61.7). A high incidence of necrosis, extraglandular spread, lymphovascular invasion (LVI), atypical mitosis, and cellular pleomorphism was observed in the high-risk tumors compared to the low-risk ones.
CONCLUSION
CONCLUSIONS
AciCC generally had an indolent behavior, optimal OS, DFS with few cervical node metastases, and rare distant relapses. This multicenter retrospective case series provides evidence of the need for clinical-epidemiological-histological stratification for patients at risk of poor outcomes. Our results suggest that the correct definition of high-risk AciCC should include tumor size, the presence of necrosis, extraglandular spread, LVI, atypical mitosis, and cellular pleomorphism.
Identifiants
pubmed: 38001716
pii: cancers15225456
doi: 10.3390/cancers15225456
pmc: PMC10669973
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Arch Otorhinolaryngol. 2020 Oct;277(10):2673-2679
pubmed: 32367151
Oral Oncol. 2022 Feb;125:105698
pubmed: 34973520
Cancer Cytopathol. 2021 Dec;129(12):973-983
pubmed: 34379894
Clin Case Rep. 2023 Jul 17;11(7):e7512
pubmed: 37469364
Head Neck Pathol. 2022 Sep;16(3):870-875
pubmed: 34870795
Pathol Res Pract. 2020 Feb;216(2):152767
pubmed: 31812438
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):542-549.e1
pubmed: 27017401
Clin Exp Otorhinolaryngol. 2021 Feb;14(1):108-115
pubmed: 32392906
BMC Cancer. 2020 Jul 8;20(1):631
pubmed: 32641007
Pathol Res Pract. 1994 Feb;190(2):115-23
pubmed: 8058567
Head Neck Pathol. 2022 Mar;16(1):40-53
pubmed: 35312980
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nat Commun. 2019 Jan 21;10(1):368
pubmed: 30664630
Am J Surg Pathol. 2012 Mar;36(3):343-50
pubmed: 22301503
Braz Oral Res. 2023 May 29;37:e050
pubmed: 37255070
Eur Arch Otorhinolaryngol. 2022 Dec;279(12):5821-5829
pubmed: 35678874
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Am J Surg Pathol. 2009 Aug;33(8):1137-45
pubmed: 19461506
Cancer. 2009 May 15;115(10):2128-37
pubmed: 19309749
Head Neck. 1999 Jul;21(4):297-309
pubmed: 10376748
Head Neck Pathol. 2016 Jun;10(2):152-60
pubmed: 26245749
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3307-12
pubmed: 26861548
Front Med (Lausanne). 2023 Jul 03;10:1163565
pubmed: 37465638
JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1011-1016
pubmed: 29978180
Am J Surg Pathol. 2022 Jul 1;46(7):933-941
pubmed: 35034042
J Clin Med. 2019 Aug 27;8(9):
pubmed: 31461946
Surg Gynecol Obstet. 1953 Oct;97(4):401-16
pubmed: 13102167
Am J Pathol. 1954 May-Jun;30(3):465-77
pubmed: 13158522
Ann Otol Rhinol Laryngol. 2010 Oct;119(10):677-83
pubmed: 21049853
Otolaryngol Head Neck Surg. 1988 Feb;98(2):155-61
pubmed: 3128758
Cancers (Basel). 2022 Mar 18;14(6):
pubmed: 35326709